TG Therapeutics, Inc. (NASDAQ:TGTX)‘s stock had its “buy” rating reaffirmed by research analysts at SunTrust Banks, Inc. in a research report issued to clients and investors on Tuesday. They presently have a $28.00 target price on the biopharmaceutical company’s stock. SunTrust Banks, Inc.’s price target suggests a potential upside of 133.33% from the stock’s current price.

TGTX has been the subject of a number of other reports. FBR & Co reiterated a “buy” rating on shares of TG Therapeutics in a report on Saturday, June 17th. Zacks Investment Research downgraded shares of TG Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 12th. BidaskClub downgraded shares of TG Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 5th. Finally, Jefferies Group LLC reaffirmed a “buy” rating and set a $23.00 target price on shares of TG Therapeutics in a research report on Monday, June 5th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and ten have assigned a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $25.40.

Shares of TG Therapeutics (NASDAQ TGTX) remained flat at $12.00 during mid-day trading on Tuesday. The company’s stock had a trading volume of 1,184,670 shares. TG Therapeutics has a 52 week low of $4.10 and a 52 week high of $15.35. The stock’s market capitalization is $747.72 million. The firm has a 50-day moving average of $11.83 and a 200-day moving average of $11.33.

TG Therapeutics (NASDAQ:TGTX) last released its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.45) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.46) by $0.01. The firm had revenue of $0.04 million for the quarter, compared to analyst estimates of $0.04 million. TG Therapeutics had a negative return on equity of 154.02% and a negative net margin of 68,806.59%. Analysts forecast that TG Therapeutics will post ($1.84) EPS for the current fiscal year.

WARNING: This piece was originally reported by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another domain, it was stolen and republished in violation of US & international trademark and copyright law. The legal version of this piece can be read at https://www.watchlistnews.com/tg-therapeutics-inc-tgtx-rating-reiterated-by-suntrust-banks-inc/1606172.html.

Hedge funds have recently modified their holdings of the stock. FMR LLC boosted its stake in TG Therapeutics by 70.2% during the first quarter. FMR LLC now owns 6,451,713 shares of the biopharmaceutical company’s stock worth $75,162,000 after buying an additional 2,660,949 shares in the last quarter. State Street Corp raised its stake in shares of TG Therapeutics by 274.4% in the 2nd quarter. State Street Corp now owns 2,638,683 shares of the biopharmaceutical company’s stock valued at $26,515,000 after buying an additional 1,933,896 shares in the last quarter. Franklin Resources Inc. raised its stake in shares of TG Therapeutics by 20.6% in the 2nd quarter. Franklin Resources Inc. now owns 2,339,166 shares of the biopharmaceutical company’s stock valued at $23,509,000 after buying an additional 398,916 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of TG Therapeutics by 14.3% in the 2nd quarter. Vanguard Group Inc. now owns 2,046,427 shares of the biopharmaceutical company’s stock valued at $20,566,000 after buying an additional 255,844 shares in the last quarter. Finally, Columbus Circle Investors raised its stake in shares of TG Therapeutics by 39.0% in the 2nd quarter. Columbus Circle Investors now owns 1,396,396 shares of the biopharmaceutical company’s stock valued at $14,034,000 after buying an additional 391,975 shares in the last quarter. 49.89% of the stock is owned by hedge funds and other institutional investors.

TG Therapeutics Company Profile

TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes.

Analyst Recommendations for TG Therapeutics (NASDAQ:TGTX)

Receive News & Ratings for TG Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.